| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.092 | 0.08 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.08 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.08 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.062 | 0.09 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.091 | 0.09 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.06 | 0.09 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.09 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.09 |